Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Cohen, T. Karrison, M. Kocherginsky, Jeffrey Mueller, R. Egan, C. Huang, B. Brockstein, M. Agulnik, B. Mittal, F. Yunus, S. Samant, L. Raez, R. Mehra, Priya Kumar, F. Ondrey, Patrice Marchand, Bettina Braegas, T. Seiwert, V. Villaflor, D. Haraf, E. Vokes (2014)
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 25
MG Ghi, A Paccagnella, D Ferrari (2014)
Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Flourouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN)J Clin Oncol, 32
M. Regan, B. Walley, G. Fleming, M. Colleoni, I. Láng, H. Gómez, C. Tondini, H. Burstein, E. Perez, E. Ciruelos, V. Stearns, H. Bonnefoi, S. Martino, C. Geyer, M. Rabaglio-Poretti, A. Coates, R. Gelber, A. Goldhirsch, P. Francis (2014)
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 18_suppl
R. Haddad, A. O'neill, G. Rabinowits, R. Tishler, F. Khuri, D. Adkins, Joseph Clark, N. Sarlis, J. Lorch, J. Beitler, S. Limaye, S. Riley, M. Posner (2013)
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.The Lancet. Oncology, 14 3
O. Yu, M. Eberg, S. Benayoun, A. Aprikian, G. Batist, S. Suissa, L. Azoulay (2014)
Use of statins and the risk of death in patients with prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 1
D. Niedzwiecki, H. Lenz, F. Innocenti, M. Mahoney, B. O'Neil, J. Shaw, B. Polite, H. Hochster, J. Atkins, R. Goldberg, R. Mayer, R. Schilsky, M. Bertagnolli, C. Blanke (2014)
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 18_suppl
N. Thatcher, F. Hirsch, A. Szczesna, T. Ciuleanu, W. Szafrański, M. Dediu, R. Ramlau, R. Galiulin, B. Bálint, G. Losonczy, A. Każarnowicz, Keunchil Park, C. Schumann, M. Reck, L. Paz-Ares, H. Depenbrock, S. Nanda, Anamarija Kruljac-Letunic, M. Socinski (2014)
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).Journal of Clinical Oncology, 32
G. Long, D. Stroyakovsky, H. Gogas, E. Levchenko, F. Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. Grob, V. Chiarion-Sileni, C. Lebbé, M. Mandalà, M. Millward, D. Demarini, J. Irani, N. Le, M. Casey, K. Patel, K. Flaherty (2014)
COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanomaJournal of Clinical Oncology, 32
R. Hitt, J. Grau, A. López-pousa, A. Berrocal, C. García-Girón, A. Irigoyen, J. Sastre, J. Martínez-Trufero, J. Castelo, E. Verger, J. Cruz-Hernández, C. Almodóvar, H. Cortés-Funes, Y. Escobar, E. Fonseca-Sánchez, J. Galcerán, M. Guix, D. Isla-Casado, C. Jara-Sánchez, M. Leitão-Silva, J. Mel-Lorenzo, M. Pastor-Borgoñón, P. Pastor-Gaitán, A. Rodríguez-Jaráiz, J. Millán, J. Satrustegui-Galdona, M. Moreno, E. Estefanía, E. Santiago, J. García (2014)
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 25 1
M. Ghi, A. Paccagnella, D. Ferrari, P. Foa, M. Rocca, E. Verri, F. Morelli, G. Azzarello, C. D'Ambrosio, G. Cruciani, M. Guaraldi, E. Massa, C. Rossetto, A. Bonetti, S. Siena, V. Minotti, H. Koussis, G. Pieri, V. Baggio, I. Floriani (2014)
Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826).Journal of Clinical Oncology, 32
S. Stintzing, A. Jung, Lisa Rossius, D. Modest, L. Weikersthal, T. Decker, A. Kiani, S. Al-Batran, U. Vehling‐Kaiser, T. Heintges, M. Moehler, W. Scheithauer, T. Kirchner, V. Heinemann (2014)
Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.Journal of Clinical Oncology, 32
JC Yang, LV Sequist, M Schuler (2014)
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFRmut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 and LUX-Lung 6) comparing afatinib with chemotherapy (CT)J Clin Oncol, 32
MJ Piccart-Gebhart, AP Holmes, J Baselga (2014)
First results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancerJ Clin Oncol, 32
editorial memo (2014) 7:196–197 DOI 10.1007/s12254-014-0189-x Wolfgang Eisterer Received: 6 November 2014 / Accepted: 17 November 2014 / Published online: 28 November 2014 © Springer-Verlag Wien 2014 Wolfgang Eisterer This year’s American Society of Clinical Oncology (ASCO) In the treatment of locally advanced head and neck saw some major improvements in the treatment of tumors concomitant chemoradiotherapy is considered as patients with solid tumors which, however, did not lead standard of care. Owing to the fact that systemic relapse to a change in current clinical practice; at least not in the occurs frequently during follow-up in these patients treatment of those solid tumors which will be reported strategies that include systemic therapy have been devel- within this summary. Surprisingly not all the therapeutic oped. Special interest has focused on the concept of progress stems from targeted therapy but also from long- sequential therapy meaning induction chemotherapy known substances like aromatase inhibitors. In total, before chemoradiotherapy. Numerous phase III stud- more than 5000 abstracts have been presented at ASCO ies have failed to show an improvement in survival for 2014. Within this review the most important abstracts cov- induction chemotherapy [3–5]. An Italian phase III study ering head and neck
memo - Magazine of European Medical Oncology – Springer Journals
Published: Nov 28, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.